Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Pn-MAPS30plus in Adults 50 To 64 Years of Age
NCT07105722Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK5459248 in bacterial pneumonia (2 arms), sponsored by GSK. Primary endpoints: Number of Participants with Each Solicited Administration Site (Local) Event at 7 days, Number of Participants with Each Solicited Systemic Event at 7 days and 3 more. Started Aug 2025; status: completed.
02
Drugs
GSK5459248
03
Conditions
bacterial pneumonia
Beyond the preview
Go deeper on NCT07105722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105722.